Astec Lifesciences Ltd, Birlasoft Ltd, Dollar Industries Ltd and Natco Pharma Ltd are among the other gainers in the BSE s A group today, 24 May 2021.
Astec Lifesciences Ltd, Birlasoft Ltd, Dollar Industries Ltd and Natco Pharma Ltd are among the other gainers in the BSE s A group today, 24 May 2021.
JTEKT India Ltd spiked 17.40% to Rs 112.65 at 11:49 IST. The stock was the biggest gainer in the BSE s A group. On the BSE, 4.9 lakh shares were traded on the counter so far as against the average daily volumes of 26828 shares in the past one month.
Astec Lifesciences Ltd soared 15.68% to Rs 1473.05. The stock was the second biggest gainer in A group. On the BSE, 17721 shares were traded on the counter so far as against the average daily volumes of 19491 shares in the past one month.
Natco Pharma gets USFDA nod for two products
Updated:
Updated:
May 22, 2021 16:17 IST
Natco and Arrow will launch the approved product on agreed-upon launch dates in the future, a release said.
Share Article
AAA
Natco and Arrow will launch the approved product on agreed-upon launch dates in the future, a release said. Natco Pharma has received final approval from the U.S. Food and Drug Administration for abbreviated new drug applications (ANDA) for two products, including an anti-cancer drug for which the company and its marketing partner had settled a litigation with Celgene.
On Lenalidomide capsules, which is indicated in treatment of certain types of cancers, Natco said it has received final approval for 5mg, 10mg, 15mg, and 25mg strengths and tentative approval of the 2.5 mg and 20mg strengths.
Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celgene, now part of Bristol-Myers Squibb, who sells the product under the brand name Revlimid , it added.
Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild COVID-19. The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals. Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir capsules in mild COVID-19 patients, Natco Pharma said in a regulatory filing. The clinical trial is planned in 32 hospitals across the country. Pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, the drug firm noted.
Walk the talk on TRIPS waiver
Updated:
Updated:
The government should offer Covaxin’s technology to domestic pharmaceutical companies and foreign corporations
Share Article
The government should offer Covaxin’s technology to domestic pharmaceutical companies and foreign corporations
Member countries of the World Trade Organization (WTO) are under an obligation to ensure that their domestic intellectual property rights (IPR) laws conform to the requirements of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. When the pandemic hit the globe, India and South Africa piloted the proposal to waive key provisions of the TRIPS agreement on COVID-19 vaccines, drugs, therapeutics, and related technologies. The core idea is that IPRs such as patents should not become barriers in scaling up production of medical products essential to combat COVID-19. The TRIPS waiver proposal, now backed by the U.S., is essential because it would give immunity to member coun